Navigation Links
Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients

reactions and cardiopulmonary arrest, visit http://www.ERBITUX.com.

Important Safety Information

Grade 3/4 infusion reactions, rarely with fatal outcome (<1 in 1000), occurred in approximately 3% (46/1485) of patients receiving ERBITUX (Cetuximab) therapy. These reactions are characterized by rapid onset of airway obstruction (bronchospasm, stridor, hoarseness), urticaria, hypotension, and/or cardiac arrest. Severe infusion reactions require immediate and permanent discontinuation of ERBITUX therapy.

Most reactions (90%) were associated with the first infusion of ERBITUX despite the use of prophylactic antihistamines. Caution must be exercised with every ERBITUX infusion as there were patients who experienced their first severe infusion reaction during later infusions. A 1-hour observation period is recommended following the ERBITUX infusion. Longer observation periods may be required in patients who experience infusion reactions.

Cardiopulmonary arrest and/or sudden death occurred in 2% (4/208) of patients with squamous cell carcinoma of the head and neck treated with radiation therapy and ERBITUX as compared to none of 212 patients treated with radiation therapy alone. Fatal events occurred within 1 to 43 days after the last ERBITUX treatment. ERBITUX in combination with radiation therapy should be used with caution in patients with known coronary artery disease, congestive heart failure and arrhythmias. Close monitoring of serum electrolytes, including serum magnesium, potassium, and calcium during and after ERBITUX therapy is recommended.

Severe cases of interstitial lung disease (ILD), which was fatal in one case, occurred in less than 0.5% of 774 patients with advanced colorectal cancer (mCRC) receiving ERBITUX. There was one case of ILD reported in 796 patients with head and neck cancer receiving ERBITUX in clinical studies.

In clinical studies of ERBITUX, dermato
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/31/2015)... LAKE, N.J. and SAN DIEGO ... today that its parent company Eisai Co., Ltd. (Headquarters: ... Haruo Naito , "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: ... CEO: Dr. Helen Torley , "NASDAQ: HALO") have ... mesylate (brand name: Halaven ® , "eribulin") in combination ...
(Date:7/31/2015)... 2015 Magnaquest, a leading ... and cloud computing operators has signed a Proof ... for Internet of Things (IoT) related initiative. The ... subscription model.      (Logo: http://photos.prnewswire.com/prnh/20140807/700645 ... for business innovations to make healthcare services more ...
(Date:7/30/2015)... DIEGO , July 30, 2015 /PRNewswire/ ... it has signed a definitive agreement to ... of non-invasive ventilation and sleep-disordered breathing medical ... clinical, innovation and market reputation in China, combined with ResMed,s global leadership in ... people in China ...
Breaking Medicine Technology:Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Remedi SeniorCare®, one of the nation,s largest ... innovative solution for the long-term care industry -- ... long-term care facilities to more efficiently and ... This includes complex medication orders, electronic health ...
... 2012 Span-America Medical Systems, Inc. (NASDAQ:  SPAN) will ... conference call on Friday, February 3, 2012, covering results ... released after the regular close of trading the preceding ... call will be available online at www.spanamerica.com ...
Cached Medicine Technology:Connexit™ Launch Aims to Reshape Business of Long-Term Care 2Connexit™ Launch Aims to Reshape Business of Long-Term Care 3
(Date:7/31/2015)... ... ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) convened a ... July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central and Latin ... Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, Department of ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... currently going on in Chicago at Grant Park. The festival will end on ... North America to Chicago for the annual Lollapalooza. This unique and unbelievably popular ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... five new industry players to know in predictive health analytics , Jvion ... learning technologies. The firm creates predictive software that targets patient and population level ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride ... in Downtown Memphis on October 3, 2015. The Ride to Fight On is a ... research between Methodist Healthcare, The West Clinic and The University of Tennessee Health Science ...
(Date:7/31/2015)... ... July 31, 2015 , ... There’s no better way to enjoy the summer ... to cook the next meal, making July the most appropriate to be National Hot ... and recipes. , Make the next cookout different than the ones in the past. ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... of alcohol abuse costs each Canadian $463 per year. ... abuse in Canada exceed those of cancer. Released today ... Avoidable Cost of Alcohol Abuse in Canada 2002 report estimates ... would result in cost savings of about $1 billion per ...
... much the way alcohol, Alzheimer,s do , , WEDNESDAY, June ... tissue loss in brain regions that help store memory, ... , "Our findings demonstrate that impaired breathing during sleep ... and thinking," principal investigator Ronald Harper, a professor of ...
... IT will Provide Immediate Access to Vital Patient ... ... Jim Traficant,vice president of Harris Corporation,s (NYSE: HRS ) ... Care,Administration (AHCA), and provided a patient,s perspective of healthcare,policy. Traficant projected ...
... of the 1000 Genomes Project announced today that three ... have joined the international effort to build the most ... a tool for medical research. The new participants are: ... Biosystems, an Applera Corp. business, Foster City, Calif.; and ...
... Ill. Primary snoring in children may have an ... obstructive sleep apnea (OSA), according to a research abstract ... 22nd Annual Meeting of the Associated Professional Sleep Societies ... colleagues at the University of Melbourne and Monash University, ...
... cognitive behavioral intervention for insomnia delivered via the Internet ... research abstract that will be presented on Wednesday at ... Professional Sleep Societies (APSS). , The study, authored by ... on 44 participants (mostly female) with an average age ...
Cached Medicine News:Health News:Save $1 billion and 800 lives 2Health News:Save $1 billion and 800 lives 3Health News:Sleep Apnea Linked to Memory Loss 2Health News:Harris Corporation's Jim Traficant Addresses Florida Agency for Health Care Administration 2Health News:3 sequencing companies join 1000 Genomes Project 2Health News:3 sequencing companies join 1000 Genomes Project 3Health News:3 sequencing companies join 1000 Genomes Project 4Health News:3 sequencing companies join 1000 Genomes Project 5Health News:Primary snoring in children impacts cardiovascular functioning 2Health News:Primary snoring in children impacts cardiovascular functioning 3Health News:A self-help program delivered online can improve insomnia in adults 2
... unique fiberoptic laryngoscope blade that can give ... needed during difficult intubations. The articulating tip ... to be raised by squeezing a lever ... produces a more complete exposure of the ...
... laryngoscope handles can be used with Portex® ... sturdy chrome blades with long-lasting bronze fiber-optic ... for continuous routine use., ,The laryngoscope ... of sizes, from infant to large adult, ...
... handles can be used with Portex® reusable ... chrome blades with long-lasting bronze fiber-optic bundles ... continuous routine use., ,The laryngoscope blades ... sizes, from infant to large adult, and ...
... an innovative intubation system. Providing an unobstructed ... is ideal for many types of intubations., ... embedded within the patented Glidescope blade. Clear ... displayed on a monitor screen. An LED ...
Medicine Products: